In 2026, global biopharma mergers and acquisitions have surged, with deal values reaching $106 billion across 201 transactions as of early June. This pace suggests a potential total exceeding $250 billion for the year, marking a significant rebound since pre-pandemic levels. Pharmaceutical companies are actively acquiring assets to counteract impending patent expiries for blockbuster drugs, focusing on strategic acquisitions valued between $1 billion and $5 billion, prioritizing products close to commercialization and innovative technologies. Key deals include Sun Pharma’s $11.75 billion acquisition of Organon, Gilead’s $7.8 billion purchase of Arcellx, and Merck’s $6.7 billion acquisition of Terns Pharmaceuticals, among others. Additionally, the State Street SPDR S&P Biotech ETF has gained 9% year-to-date, reflecting positive market sentiment.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.tradingview.com/news/stocktwits:76d3d700c094b:0-gilead-merck-eli-lilly-lead-106b-biopharma-takeover-wave-in-2026/
